Perspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With Polyangiitis

Two types of interleukin (IL)-5 antibody biologics, anti-IL-5 antibodies (mepolizumab) and anti-IL-5α receptor antibodies (benralizumab), are indicated for severe asthma. While high-dose mepolizumab is also indicated for EGPA, benralizumab is indicated only for severe asthma. Benralizumab is charact...

Descripción completa

Detalles Bibliográficos
Autores principales: Koga, Yasuhiko, Aoki-Saito, Haruka, Kamide, Yosuke, Sato, Makiko, Tsurumaki, Hiroaki, Yatomi, Masakiyo, Ishizuka, Tamotsu, Hisada, Takeshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960447/
https://www.ncbi.nlm.nih.gov/pubmed/35359852
http://dx.doi.org/10.3389/fphar.2022.865318

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960447/
https://www.ncbi.nlm.nih.gov/pubmed/35359852
http://dx.doi.org/10.3389/fphar.2022.865318

Ejemplares similares